Compare HYPR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYPR | MAIA |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | 102 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.1M | 79.0M |
| IPO Year | 2021 | 2022 |
| Metric | HYPR | MAIA |
|---|---|---|
| Price | $0.94 | $1.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $1.59 | N/A |
| AVG Volume (30 Days) | ★ 887.0K | 592.5K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.21 | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,563,000.00 | N/A |
| Revenue This Year | $50.75 | N/A |
| Revenue Next Year | $29.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.22 | N/A |
| 52 Week Low | $0.85 | $0.87 |
| 52 Week High | $2.22 | $3.19 |
| Indicator | HYPR | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 34.34 | 36.77 |
| Support Level | $0.88 | $1.13 |
| Resistance Level | $1.19 | $1.48 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 29.00 | 5.88 |
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.